Novanta Inc (1GSN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novanta Inc (1GSN) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€8.49 Million ≈ $9.93 Million USD) by net assets (€801.48 Million ≈ $937.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 1GSN market cap overview for the company's overall valuation and market capitalisation.
Novanta Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Novanta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novanta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novanta Inc ranked by their cash flow conversion efficiency. Explore 1GSN operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR
|
0.014x |
|
KONINKLIJKE VOP.UNSP.ADR
F:VPK
|
N/A |
|
Premier Energies Limited
NSE:PREMIERENE
|
0.144x |
|
Choice Hotels International Inc
NYSE:CHH
|
0.637x |
|
Hongda
SHG:600331
|
-0.083x |
|
Union Bank of Taiwan Pref
TW:2838A
|
-0.155x |
|
Acm Research Inc
NASDAQ:ACMR
|
-0.014x |
|
Page Industries Limited
NSE:PAGEIND
|
0.356x |
Annual Cash Flow Conversion Efficiency for Novanta Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Novanta Inc from 2015 to 2024. View latest Novanta Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €745.70 Million ≈ $871.80 Million |
€158.51 Million ≈ $185.32 Million |
0.213x | +19.22% |
| 2023-12-31 | €673.46 Million ≈ $787.35 Million |
€120.08 Million ≈ $140.38 Million |
0.178x | +13.44% |
| 2022-12-31 | €577.59 Million ≈ $675.26 Million |
€90.78 Million ≈ $106.13 Million |
0.157x | -13.41% |
| 2021-12-31 | €521.29 Million ≈ $609.44 Million |
€94.62 Million ≈ $110.63 Million |
0.182x | -38.28% |
| 2020-12-31 | €476.81 Million ≈ $557.44 Million |
€140.24 Million ≈ $163.95 Million |
0.294x | +94.00% |
| 2019-12-31 | €417.17 Million ≈ $487.72 Million |
€63.25 Million ≈ $73.94 Million |
0.152x | -37.72% |
| 2018-12-31 | €368.25 Million ≈ $430.53 Million |
€89.65 Million ≈ $104.81 Million |
0.243x | +19.67% |
| 2017-12-31 | €311.55 Million ≈ $364.23 Million |
€63.38 Million ≈ $74.10 Million |
0.203x | +10.20% |
| 2016-12-31 | €258.87 Million ≈ $302.65 Million |
€47.79 Million ≈ $55.87 Million |
0.185x | +35.18% |
| 2015-12-31 | €244.70 Million ≈ $286.08 Million |
€33.42 Million ≈ $39.07 Million |
0.137x | -- |
About Novanta Inc
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. It operates in two segments, Automation Enabling Technologies and Medical Solutions. The Precision Medicine and Manufacturing segment designs, manufactures, and markets las… Read more